Etanercept in the treatment of plaque psoriasis

References

• DubertretLMrowietzURankiAvan de KerkhofPCChimentiSLottiTEuropean patient perspectives on the impact of psoriasis: the EUROPSO patient membership surveyBr J Dermatol200615572973616965422
   PubMed Web of Science ®Google Scholar
• GottliebABChaoCDannFPsoriasis comorbiditiesJ Dermatolog Treat20081952118273720
   PubMed Web of Science ®Google Scholar
• FinlayAYColesECThe effect of severe psoriasis on the quality of life of 369 patientsBr J Dermatol19951322362447888360
   PubMed Web of Science ®Google Scholar
• KruegerGKooJLebwohlMMenterASternRSRolstadTThe impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol200113728028411255325
   PubMed Web of Science ®Google Scholar
• WuYMillsDBalaMPsoriasis: cardiovascular risk factors and other disease comorbiditiesJ Drugs Dermatol2008737337718459519
   PubMed Web of Science ®Google Scholar
• ChristophersEComorbidities in psoriasisClin Dermatol20072552953418021889
   PubMed Web of Science ®Google Scholar
• DembicZLoetscherHGublerUPanYCLahmHWGentzRTwo human TNF receptors have similar extracellular, but distinct intracellular, domain sequencesCytokine199022312371966549
   PubMedGoogle Scholar
• MohlerKMTorranceDSSmithCAGoodwinRGStremlerKEFungVPSoluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonistsJ Immunol1993151154815618393046
   PubMed Web of Science ®Google Scholar
• Etanercept [package insert]. Seattle, WA: Immunex Corporation and Wyeth-Ayerst Pharmaceuticals; 2008
   Google Scholar
• KeystoneECSafety of biologic therapies – an updateJ Rheumatol Suppl20057481215742458
   PubMedGoogle Scholar
• SpahnTWEugsterHPFontanaADomschkeWKucharzikTRole of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathwayInfect Immun2005737077708816239501
   PubMed Web of Science ®Google Scholar
• GudbrandsdottirSLarsenRSorensenLKNielsenSHansenMBSvensonMTNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritisClin Exp Rheumatol20042211812415005015
   PubMed Web of Science ®Google Scholar
• EttehadiPGreavesMWWallachDAderkaDCampRDElevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesionsClin Exp Immunol1994961461518149659
   PubMed Web of Science ®Google Scholar
• KruegerJGThe immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol200246123 quiz-611756941
   PubMed Web of Science ®Google Scholar
• CatrinaAILampaJErnestamSaf KlintEBrattJKlareskogLAnti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritisRheumatology (Oxford)20024148448912011369
   PubMed Web of Science ®Google Scholar
• BonifatiCCarducciMCordiali FeiPTrentoESacerdotiGFazioMCorrelated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients–relationships with disease severityClin Exp Dermatol1994193833877955493
   PubMed Web of Science ®Google Scholar
• MussiABonifatiCCarducciMD’AgostoGPimpinelliFD’UrsoDSerum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasisJ Biol Regul Homeost Agents1997111151189498161
   PubMed Web of Science ®Google Scholar
• BockDPhilippSWolffGTherapeutic potential of selectin antagonists in psoriasisExpert Opin Investig Drugs200615963979
   PubMed Web of Science ®Google Scholar
• ZhouHClinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion proteinJ Clin Pharmacol20054549049715831771
   PubMed Web of Science ®Google Scholar
• DonBRSpinGNestorovIHutmacherMRoseAKaysenGAThe pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysisJ Pharm Pharmacol2005571407141316259772
   PubMed Web of Science ®Google Scholar
• ZhouHBuckwalterMBoniJMayerPRaibleDWajdulaJPopulation-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritisInt J Clin Pharmacol Ther20044226727615176649
   PubMed Web of Science ®Google Scholar
• NestorovIZitnikRDeVriesTNakanishiAMWangABanfieldCPharmacokinetics of subcutaneously administered etanercept in subjects with psoriasisBr J Clin Pharmacol20066243544516995864
   PubMed Web of Science ®Google Scholar
• ZhouHMayerPRWajdulaJFatenejadSUnaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritisJ Clin Pharmacol2004441235124315496641
   PubMed Web of Science ®Google Scholar
• ZhouHParksVPatatALe CozFSimcoeDKorth-BradleyJAbsence of a clinically relevant interaction between etanercept and digoxinJ Clin Pharmacol2004441244125115496642
   PubMed Web of Science ®Google Scholar
• ZhouHPatatAParksVBuckwalterMMetzgerDKorth-BradleyJAbsence of a pharmacokinetic interaction between etanercept and warfarinJ Clin Pharmacol20044454355015102876
   PubMed Web of Science ®Google Scholar
• MenterAGottliebAFeldmanSRVan VoorheesASLeonardiCLGordonKBGuidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJ Am Acad Dermatol20085882685018423260
   PubMed Web of Science ®Google Scholar
• van de KerkhofPCSegaertSLahfaMLugerTAKarolyiZKaszubaAOnce weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extensionBr J Dermatol20081591177118518673365
   PubMed Web of Science ®Google Scholar
• Enbrel^® Summary of Product CharacteristicsWyeth Europa LtdMaidenhead2005
   Google Scholar
• BoehnckeWHBrasieRABarkerJChimentiSDaudenEde RieMRecommendations for the use of etanercept in psoriasis: a European dermatology expert group consensusJ Eur Acad Dermatol Venereol20062098899816922950
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaMPrinzJGriffithsCENakanishiAMA global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol20051521304131215948997
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTGoffeBSZitnikRWangAEtanercept as monotherapy in patients with psoriasisN Engl J Med20033492014202214627786
   PubMed Web of Science ®Google Scholar
• TyringSGottliebAPappKGordonKLeonardiCWangAEtanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialLancet2006367293516399150
   PubMed Web of Science ®Google Scholar
• GottliebABMathesonRTLoweNKruegerGGKangSGoffeBSA randomized trial of etanercept as monotherapy for psoriasisArch Dermatol200313916271632 discussion 3214676082
   PubMed Web of Science ®Google Scholar
• MooreAGordonKBKangSGottliebAFreundlichBXiaHAA randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasisJ Am Acad Dermatol20075659860317113190
   PubMed Web of Science ®Google Scholar
• FeldmanSRKimballABKruegerGGWoolleyJMLallaDJahreisAEtanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trialJ Am Acad Dermatol20055388788916243150
   PubMed Web of Science ®Google Scholar
• GordonKKormanNFrankelEWangHJahreisAZitnikREfficacy of etanercept in an integrated multistudy database of patients with psoriasisJ Am Acad Dermatol200654S101S11116488320
   PubMed Web of Science ®Google Scholar
• GottliebABLeonardiCLGoffeBSOrtonneJPvan der KerkhofPCZitnikREtanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy databaseJ Am Acad Dermatol200654S92S10016488335
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGFinlayAYGriffithsCEWoolleyJMLallaDPatient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trialBr J Dermatol20051531192119916307657
   PubMed Web of Science ®Google Scholar
• TyringSGordonKBPoulinYLangleyRGGottliebABDunnMLong-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasisArch Dermatol200714371972617576937
   PubMed Web of Science ®Google Scholar
• StroberBGALeonardiCPoster P2890 presented at: American Academy of Dermatology 64th Annual MeetingMarch 3–7, 2006San Francisco, California
   Google Scholar
• HotamisligilGSArnerPCaroJFAtkinsonRLSpiegelmanBMIncreased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistanceJ Clin Invest199595240924157738205
   PubMed Web of Science ®Google Scholar
• PallerASSiegfriedECLangleyRGGottliebABPariserDLandellsIEtanercept treatment for children and adolescents with plaque psoriasisN Engl J Med200835824125118199863
   PubMed Web of Science ®Google Scholar
• MarcilISternRSSquamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover studyLancet20013581042104511589933
   PubMed Web of Science ®Google Scholar
• PaulCFHoVCMcGeownCChristophersESchmidtmannBGuillaumeJCRisk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort studyJ Invest Dermatol200312021121612542524
   PubMed Web of Science ®Google Scholar
• SmithECRiddleCMenterMALebwohlMCombining systemic retinoids with biologic agents for moderate to severe psoriasisInt J Dermatol20084751451818412874
   PubMed Web of Science ®Google Scholar
• SmithKJSkeltonHGRapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapyJ Am Acad Dermatol20014595395611712048
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPGoughAKaldenJMalaiseMTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet200436367568115001324
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFCHallSDurezPChangDJRobertsonDComparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialLancet200837237538218635256
   PubMed Web of Science ®Google Scholar
• CatherJCMenterACombining traditional agents and biologics for the treatment of psoriasisSemin Cutan Med Surg200524374515900797
   PubMed Web of Science ®Google Scholar
• StroberBESuccessful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximabArch Dermatol200414036615023789
   PubMedGoogle Scholar
• StroberBEClarkeSEtanercept for the treatment of psoriasis: combination therapy with other modalitiesJ Drugs Dermatol2004327027215176161
   PubMedGoogle Scholar
• DriessenRJvan de KerkhofPCde JongEMEtanercept combined with methotrexate for high-need psoriasisBr J Dermatol200815946046318547310
   PubMed Web of Science ®Google Scholar
• ZachariaeCN-JMReunalaTLorentzenHThe Combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effecd\t of methotrexate therapyActa Derm Venereol20088849550118779890
   PubMed Web of Science ®Google Scholar
• ConleyJNantonJDhawanSPearceDJFeldmanSRNovel combination regimens: biologics and acitretin for the treatment of psoriasis – a case seriesJ Dermatolog Treat200617868916766332
   PubMed Web of Science ®Google Scholar
• GisondiPDel GiglioMCotenaCGirolomoniGCombining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trialBr J Dermatol20081581345134918410408
   PubMed Web of Science ®Google Scholar
• PappKAEtanercept in psoriasisExpert Opin Pharmacother200452139214615461549
   PubMed Web of Science ®Google Scholar
• LeeSJKavanaughABiologic agents in rheumatology: safety considerationsRheum Dis Clin North Am200632Suppl 131017410696
   PubMed Web of Science ®Google Scholar
• MohanAKCoteTRBlockJAManadanAMSiegelJNBraunMMTuberculosis following the use of etanercept, a tumor necrosis factor inhibitorClin Infect Dis20043929529915306993
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationInformation for Healthcare ProfessionalsCimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab)2008 Available at: http://www.fda.gov/cder/drug/infopage/TNF_blockers/default.htm
   Google Scholar
• MontielPMSolisJAChirinosJACasisBSanchezFRodriguezSHepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patientLiver Int20082871872018433400
   PubMed Web of Science ®Google Scholar
• NathanDMAngusPWGibsonPRHepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approachJ Gastroenterol Hepatol2006211366137116911678
   PubMed Web of Science ®Google Scholar
• ZeinNNEtanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled studyJ Hepatol20054231532215791697
   PubMed Web of Science ®Google Scholar
• MaglioccoMAGottliebABEtanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 casesJ Am Acad Dermatol20045158058415389194
   PubMed Web of Science ®Google Scholar
• LovellDJReiffAIlowiteNTWallaceCAChonYLinSLSafety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritisArthritis Rheum2008581496150418438876
   PubMed Web of Science ®Google Scholar
• PappKAThe safety of etanercept for the treatment of plaque psoriasisTher Clin Risk Manag2007324525818360633
   PubMedGoogle Scholar
• SaracenoRSchipaniCMazzottaAEspositoMDi RenzoLDe LorenzoAEffect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasisPharmacol Res20085729029518400510
   PubMed Web of Science ®Google Scholar
• GisondiPCotenaCTessariGGirolomoniGAnti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort studyJ Eur Acad Dermatol Venereol20082234134418005022
   PubMed Web of Science ®Google Scholar
• ReimoldAMTNFalpha as therapeutic target: new drugs, more applicationsCurr Drug Targets Inflamm Allergy2002137739214561184
   PubMedGoogle Scholar
• FDAEarly Communication About an Ongoing Safety Review of Tumor Necrosis Factor Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia)2008
   Google Scholar
• RouxCHBrocqOBreuilVAlbertCEuller-ZieglerLPregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapyRheumatology (Oxford)20074669569817158212
   PubMed Web of Science ®Google Scholar
• HyrichKLSymmonsDPWatsonKDSilmanAJPregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population registerArthritis Rheum2006542701270216871549
   PubMed Web of Science ®Google Scholar
• Sanchez CarazoJLMahiques SantosLOliver MartinezVSafety of etanercept in psoriasis: a critical reviewDrug Saf20062967568516872241
   PubMed Web of Science ®Google Scholar
• FerraraGLosiMD’AmicoRRoversiPPiroRMeacciMUse in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective studyLancet20063671328133416631911
   PubMed Web of Science ®Google Scholar
• PrattANichollKKayLUse of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experienceRheumatology (Oxford)2007461035103617409126
   PubMed Web of Science ®Google Scholar